Kadmon Pharmaceuticals announced the availability of Ribasphere Ribapak (ribavirin tablets) 600mg for the treatment of adults with chronic Hepatitis C infection in combination with peginterferon alfa-2a who have compensated liver disease and have not been previously treated with interferon alpha.
Ribasphere Ribapak is a daily 2-pill treatment taken in the morning and evening. Finishing a RibaPak reminds patients to administer their peginterferon injection. Ribavirin is a nucleoside analogue with activity against Hepatitis C virus genotypes 1–4.
Each Ribasphere RibaPak contains a 7-day supply (14 tablets). Ribasphere RibaPak is already available in 800mg, 1,000mg, and 1,200mg dosage strengths supplied in four-sleeve cartons.
For more information call (724) 778-6100 or visit www.ribapak.com.